Phase 3
-
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
Phase 3 · randomised · 394 people · 20 sites in Netherlands · Recruiting now
-
Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer
Phase 3 · randomised · 60 people · 1 site in China · Recruiting now
-
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer
Phase 3 · randomised · 430 people · 1 site in China · Recruiting now
-
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
Phase 3 · randomised · 196 people · 1 site in China · Recruiting now
-
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Phase 3 · randomised · 108 people · 1 site in China · Recruiting now
-
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Phase 3 · randomised · 600 people · 13 sites in United States · Recruiting now
-
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Phase 3 · randomised · 254 people · 1 site in France · Recruiting now